BrainStorm Announces Positive Trials of Its ALS Drug NurOwn

BrainStorm Cell Therapeutics, an Israeli developer of adult stem cell technologies for neurodegenerative diseases, announced that the Data and Safety Monitoring Board (DSMB) met to conduct its first safety More...

BrainStorm Granted Additional US Patent for Its Autologous Stem Cell Technology

 BrainStorm Cell Therapeutics (otcqb:BCLI), a  developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the More...

BrainStorm Receives $800, 000 Non-Dilutive Grant from Israel’s Office of the Chief Scientist

–   BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), announced today that Brainstorm Cell Therapeutics Ltd. was awarded a $800, 000 non-dilutive grant from Israel’s Office of the Chief Scientist More...

Merck Serono and Kadimastem Sign MOU on Drug Screening and Discovery for Neurodegenerative Diseases

–  Yossi Ben-Yossef, CEO and Founder of Kadimastem German global pharmaceutical company Merck Serono, and Israeli Kadimastem (TASE:KDST) , a developer of human pluripotent stem cell-based More...